CRISPR-mediated gene correction links the ATP7A M1311V mutations with amyotrophic lateral sclerosis pathogenesis in one individual

CRISPR 介导的基因校正将 ATP7A M1311V 突变与一个人的肌萎缩侧索硬化症发病机制联系起来

阅读:5
作者:Yeomin Yun #, Sung-Ah Hong #, Ka-Kyung Kim, Daye Baek, Dongsu Lee, Ashwini M Londhe, Minhyung Lee, Jihyeon Yu, Zachary T McEachin, Gary J Bassell, Robert Bowser, Chadwick M Hales, Sung-Rae Cho, Janghwan Kim, Ae Nim Pae, Eunji Cheong, Sangwoo Kim, Nicholas M Boulis, Sangsu Bae, Yoon Ha

Abstract

Amyotrophic lateral sclerosis (ALS) is a severe disease causing motor neuron death, but a complete cure has not been developed and related genes have not been defined in more than 80% of cases. Here we compared whole genome sequencing results from a male ALS patient and his healthy parents to identify relevant variants, and chose one variant in the X-linked ATP7A gene, M1311V, as a strong disease-linked candidate after profound examination. Although this variant is not rare in the Ashkenazi Jewish population according to results in the genome aggregation database (gnomAD), CRISPR-mediated gene correction of this mutation in patient-derived and re-differentiated motor neurons drastically rescued neuronal activities and functions. These results suggest that the ATP7A M1311V mutation has a potential responsibility for ALS in this patient and might be a potential therapeutic target, revealed here by a personalized medicine strategy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。